44 Leukemia Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Leukemia Studies in Nashville

NCT06917079Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumo...

Nashville, TX665 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT07403721Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combi...

Nashville, TX464 participantsAmgen

View Study Details

NCT05581004Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizum...

Nashville, TX450 participantsGenentech, Inc.

View Study Details

NCT07287995Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then att...

Nashville, TX428 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Nashville, TX405 participantsArriVent BioPharma, Inc.

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Nashville, TX400 participantsBayer

View Study Details

NCT06043817Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cel...

Nashville, TX345 participantsAntares Therapeutics, Inc

View Study Details

NCT06780137Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

Nashville, TX327 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04606446Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a sin...

Nashville, TX320 participantsPfizer

View Study Details

NCT06745882Recruiting

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and ...

Nashville, TX318 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT06406114Recruiting

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of...

Nashville, TX300 participantsMassachusetts General Hospital

View Study Details

NCT07154290Recruiting

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if i...

Nashville, TX300 participantsRegeneron Pharmaceuticals

View Study Details

NCT07174583Recruiting

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC....

Nashville, TX262 participantsIDEAYA Biosciences

View Study Details

NCT07519655Recruiting

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it be...

Nashville, TX250 participantsPfizer

View Study Details

NCT06031441Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti...

Nashville, TX250 participantsGenentech, Inc.

View Study Details

NCT07288177Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. Th...

Nashville, TX240 participantsGenmab

View Study Details

NCT07325136Recruiting

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer...

Nashville, TX240 participantsBristol-Myers Squibb

View Study Details

NCT07221474Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intism...

Nashville, TX180 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06501196Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk my...

Nashville, TX170 participantsBlossomHill Therapeutics

View Study Details

NCT07227597Recruiting

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other par...

Nashville, TX170 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

Nashville, TX155 participantsNEOK Bio, Inc.

View Study Details

NCT07439653Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL...

Nashville, TX155 participantsTORL Biotherapeutics, LLC

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

Nashville, TX155 participantsNEOK Bio, Inc.

View Study Details

NCT06119685Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), a...

Nashville, TX128 participantsIndapta Therapeutics, INC.

View Study Details

NCT06514794Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

Nashville, TX125 participantsWugen, Inc.

View Study Details

NCT06414460Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability o...

Nashville, TX114 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT06950034Recruiting

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no furthe...

Nashville, TX105 participantsSolu Therapeutics, Inc

View Study Details

NCT06150664Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Do...

Nashville, TX85 participantsCompass Therapeutics

View Study Details

NCT06046495Recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSC...

Nashville, TX81 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07216443Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for ...

Nashville, TX80 participantsOrca Biosystems, Inc.

View Study Details

NCT07070219Recruiting

A Study of CTD402 in T-ALL/LBL Patients

The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age o...

Nashville, TX54 participantsBIOHENG THERAPEUTICS US LLC

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Nashville, TX52 participantsCellectis S.A.

View Study Details

NCT05546580Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat ...

Nashville, TX50 participantsOryzon Genomics S.A.

View Study Details

NCT06034275Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ h...

Nashville, TX36 participantsVincerx Pharma, Inc.

View Study Details

NCT05271292Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...

Nashville, TX36 participantsChipscreen Biosciences, Ltd.

View Study Details

NCT06533579Recruiting

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignanc...

Nashville, TX32 participantsVironexis Biotherapeutics Inc.

View Study Details

NCT06828588Recruiting

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standa...

Nashville, TX30 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT06415487Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expre...

Nashville, TX30 participantsAcepodia Biotech, Inc.

View Study Details

NCT05501665Recruiting

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

This phase I/II trial tests the safety and efficacy of split-course adaptive radiation therapy in combination with immunotherapy with or without chemotherapy for the treatment of patients with stage I...

Nashville, TX25 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT07306832Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse even...

Nashville, TX18 participantsAbbVie

View Study Details

NCT06110572Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher dose radiation to known areas of cancer (...

Nashville, TX18 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT06834282Recruiting

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

This is a ﬁrst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efﬁcacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (...

Nashville, TX18 participantsCERo Therapeutics Holdings, Inc.

View Study Details

NCT05589896Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodyspl...

Nashville, TX12 participantsOssium Health, Inc.

View Study Details

NCT06931626Recruiting

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to eva...

Nashville, TX10 participantsNerviano Medical Sciences

View Study Details

About Leukemia Clinical Trials in Nashville

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 44 leukemia clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 8,088 participants. Research is being sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), Amgen, Genentech, Inc. and 34 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Nashville — FAQ

Are there leukemia clinical trials in Nashville?

Yes, there are 44 leukemia clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 44 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 13, 2026 from ClinicalTrials.gov